Company Analysis Артген биотех (ИСКЧ)
1. Summary
Advantages
- Price (89.58 ₽) is less than fair price (138.17 ₽)
Disadvantages
- Dividends (1.13%) are below the sector average (9.08%).
- The stock's return over the last year (-15.57%) is lower than the sector average (0.25%).
- Current debt level 28.58% has increased over 5 years from 18.01%.
- The company's current efficiency (ROE=13.65%) is lower than the sector average (ROE=130.18%)
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Артген биотех (ИСКЧ) | Потреб | Index | |
|---|---|---|---|
| 7 days | 1.4% | 2.8% | 1.5% |
| 90 days | -4.2% | 17.1% | 12.2% |
| 1 year | -15.6% | 0.2% | -9.8% |
ABIO vs Sector: Артген биотех (ИСКЧ) has significantly underperformed the "Потреб" sector by -15.82% over the past year.
ABIO vs Market: Артген биотех (ИСКЧ) has significantly underperformed the market by -5.73% over the past year.
Stable price: ABIO is not significantly more volatile than the rest of the market on "Московская биржа" over the last 3 months, with typical variations of +/- 5% per week.
Long period: ABIO with weekly volatility of -0.2994% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (89.58 ₽) is lower than the fair price (138.17 ₽).
Price significantly below the fair price: The current price (89.58 ₽) is 54.2% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (164.73) is higher than that of the sector as a whole (10.89).
P/E vs Market: The company's P/E (164.73) is higher than that of the market as a whole (14.68).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (-23.6) is lower than that of the sector as a whole (30.67).
P/BV vs Market: The company's P/BV (-23.6) is lower than that of the market as a whole (10.15).
4.4. P/S
P/S vs Sector: The company's P/S indicator (6.93) is higher than that of the sector as a whole (1.43).
P/S vs Market: The company's P/S indicator (6.93) is higher than that of the market as a whole (1.91).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (41.48) is higher than that of the sector as a whole (6.26).
EV/Ebitda vs Market: The company's EV/Ebitda (41.48) is higher than that of the market as a whole (2.22).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -5.75% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-5.75%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (0%).
5.4. ROE
ROE vs Sector: The company's ROE (13.65%) is lower than that of the sector as a whole (130.18%).
ROE vs Market: The company's ROE (13.65%) is lower than that of the market as a whole (68.42%).
5.5. ROA
ROA vs Sector: The company's ROA (2.21%) is lower than that of the sector as a whole (11.14%).
ROA vs Market: The company's ROA (2.21%) is lower than that of the market as a whole (17.61%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (7.55%) is lower than that of the sector as a whole (14.31%).
ROIC vs Market: The company's ROIC (7.55%) is lower than that of the market as a whole (16.32%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 1.13% is below the average for the sector '9.08%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 1.13% has not been consistently paid over the past 7 years, DSI=0.43.
Weak dividend growth: The company's dividend yield 1.13% has been growing weakly or stagnant over the past 5 years. Growth over only 1 year.
7.3. Payout percentage
Dividend Coverage: Current payments from income (213%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
9. Stocks forum Артген биотех (ИСКЧ)
9.1. Stocks forum - Latest comments
9.2. Latest Blogs
Утренний обзор: чего ждать от рынка?
В понедельник индекс Мосбиржи закрылся в нуле.
2800 удержан, но может быть повторный штурм!
Нефть выросла на 1,5% за 2 дня на угрозах Байдена о запрете бурения скважин и все еще не особо закрепилась выше уровня 77,21 - на перекупленности можем увидеть какой-либо откат....
More
💊 Слыхали про супер-лекарство от наших фарм-компаний?
- ❌ Нет ?
Да я тоже нет, но судя по темпам роста , - оно есть.
🦠 Что там за напасть в Китае (где ж ещё опять) ?
Метапневмовирус - является одним из возбудителей респираторных инфекций, был открыт аж в в 2001 году.
Чаще всего вызывает острые респираторные инфекции, включая бронхиолит, пневмонию....
More
⚡️ Рост на завышенных ожиданиях? К чему готовиться инвестору.
Индекс МосБиржи в отсутствии продавцов со стороны нерезидентов продолжает демонстрировать силу. Следующим техническим препятствием в виде двухнедельной вершины выступает значение 2818п. Пробить его и продолжить подъем будет тяжело, при условии, если нефть сохранит нисходящую динамику даже при слабеющем рубле....
More
All blogs ⇨
